Interactions between Guanabenz and Super B Complex
No drug interactions found, but 10 warnings to review for the following 2 drugs:
- guanabenz
- Super B Complex (multivitamin)
Drug interactions
There were no interactions found between guanabenz and Super B Complex. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
guanabenz Alcohol (Ethanol)
Applies to: guanabenz
Monitor
Certain psychotherapeutic and other CNS-active agents may have blood pressure-lowering effects and may cause dizziness, orthostatic hypotension, or syncope. These effects may be more likely during treatment initiation, dose escalation, or treatment restart. Coadministration with antihypertensives or other agents with blood pressure-lowering properties, particularly vasodilators and alpha-adrenergic blockers, may result in additive hypotensive or orthostatic effects.
Management
Monitor blood pressure and clinical response during concomitant use, especially when starting or increasing the dose of either agent. Patients should be advised to rise slowly from a sitting or lying position and to report dizziness, lightheadedness, fainting, orthostasis, palpitations, or troublesome changes in pulse or heart rate. Patients should be cautioned that alcohol may enhance blood pressure-lowering effects during concomitant use with antihypertensives or other agents with hypotensive properties. Patients should avoid driving or operating hazardous machinery until they know how the medications affect them.
References (13)
- Sternbach H (1991) "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol, 11, p. 390-1
- Shook TL, Kirshenbaum JM, Hundley RF, Shorey JM, Lamas GA (1984) "Ethanol intoxication complicating intravenous nitroglycerin therapy." Ann Intern Med, 101, p. 498-9
- Feder R (1991) "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry, 52, p. 139
- Ellison JM, Milofsky JE, Ely E (1990) "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry, 51, p. 385-6
- Rodriguez de la Torre B, Dreher J, Malevany I, et al. (2001) "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit, 23, p. 435-40
- Pacher P, Kecskemeti V (2004) "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des, 10, p. 2463-75
- Andrews C, Pinner G (1998) "Postural hypotension induced by paroxetine." BMJ, 316, p. 595
- (2023) "Product Information. Buprenorphine (buprenorphine)." G.L. Pharma UK Ltd
- (2023) "Product Information. Temgesic (buprenorphine)." Reckitt Benckiser Pty Ltd
- (2026) "Product Information. Urapidil (Carinopharm) (urapidil)." Imported (EU)
- (2020) "Product Information. URAPIDIL ACCORD (urapidil)." ACCORD HEALTHCARE LIMITED
- (2020) "Product Information. Ebrantil (urapidil)." CHEPLAPHARM ARZNEIMITTEL GMBH
- (2026) "Product Information. Urapidil (urapidil)." Imported (Switzerland)
Disease interactions
9 potential interactions Applies to: 9 conditions, including Depression, Hypotension, Peripheral Arterial Disease, Liver Disease, and Heart Block.
Cerebrovascular Insufficiency
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Cerebrovascular Insufficiency.
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.
Depression
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Depression.
Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.
Heart Block
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Heart Block.
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.
Hypotension
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Hypotension.
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.
Ischemic Heart Disease
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Ischemic Heart Disease.
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.
Liver Disease
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Liver Disease.
Guanabenz is primarily metabolized by the liver. Pharmacokinetic data indicate that the plasma clearance of guanabenz is significantly reduced and its elimination half-life significantly prolonged in patients with liver disease. Therapy with guanabenz should be administered cautiously in patients with impaired hepatic function. Careful monitoring of blood pressure during dosage titration is recommended.
Peripheral Arterial Disease
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Peripheral Arterial Disease.
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.
Renal Dysfunction
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Renal Dysfunction.
The disposition of orally administered guanabenz is altered modestly in renal impairment. The manufacturer states that the plasma clearance of guanabenz is reduced and its half-life prolonged in patients with impaired renal function, and more so in those on hemodialysis. The clinical significance of these findings is unknown. Careful monitoring of blood pressure during dosage titration is recommended.
Sinus Node Dysfunction
Moderate:
guanabenz
Guanabenz has a moderate potential interaction with Sinus Node Dysfunction.
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.
Report options
More resources
guanabenz
A total of 228 drugs are known to interact with guanabenz.
- Guanabenz is in the drug class antiadrenergic agents, centrally acting.
- Guanabenz is used to treat High Blood Pressure.
Super B Complex
A total of 22 drugs are known to interact with Super B Complex.
- Super b complex is in the drug class vitamin and mineral combinations.
- Super b complex is used to treat Dietary Supplementation.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.